AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
Source:
NASDAQ Stocks
/
02 Apr 2024 09:15:53 America/Chicago
AstraZeneca AZN announced that the FDA had approved Voydeya (danicopan) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and chronic blood disorder. https://www.nasdaq.com/articles/astrazenecas-azn-rare-blood-disorder-drug-gets-fda-nod
Share on,